Shareholder rights law firm Johnson & Weaver, LLP has launched an investigation into whether the board members of Celladon Corporation (NASDAQ: CLDN) breached their fiduciary duties in connection with the proposed merger of the Company with Eiger BioPharmaceuticals, Inc. Additional Information: Celladon is a clinical-stage biotechnology company, focuses on developing cardiovascular gene therapy and calcium dysregulation. On November 19, 2015, Celladon announced that it had signed a definitive merger agreement with Eiger. The stockholders of Eiger would become the majority owners of Celladon and the operations of Celladon and Eiger would be combined. The merger needs the approval of Celladon stockholders; if approved Celladon will be renamed Eiger BioPharmaceuticals. An investor syndicate has committed to invest $39.5 million in the combined company. Under the terms of the agreement Celladon shareholders will receive newly issued shares. On a pro forma basis for the combined company, current Celladon shareholders are expected to own approximately 22%, current Eiger shareholders approximately 45% and the new Eiger investor syndicate approximately 33%, each on a fully-diluted basis. The investigation concerns whether Celladon's board is acting in the shareholders' best interests, including whether the board adequately pursued alternatives to the merger and whether the board obtained the best deal possible for the Company's shareholders. Nationally recognized Johnson & Weaver is investigating whether the proposed deal price represents adequate consideration, especially given the Company's current level of cash. As of September 30, 2015, Celladon had over 37 million in cash. If you are a shareholder of Celladon and believe the proposed deal is not fair or you're interested in learning more about the investigation or your legal rights and remedies, please contact lead analyst Jim Baker ( email@example.com) at 619-814-4471. About Johnson & Weaver, LLP: Johnson & Weaver, LLP is a nationally recognized shareholder rights law firm with offices in California, New York and Georgia. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits. For more information about the firm and its attorneys, please visit http://www.johnsonandweaver.com. Attorney advertising. Past results do not guarantee future outcomes.